Cmon guys, way too much negative banter here...all I want to see is sales figures (and FDA approval)...until then RSH has some ground to make up.
Clearly market needs to see sales to kick it along...nothing wrong with the current balance sheet, just early product uptake sometimes takes a while to get momentum
